Cavion Appoints Julia P. Gregory Executive Chair
“The addition of Julia Gregory to Cavion reinforces our commitment to bringing together an industry-leading team of seasoned business leaders and world-renowned scientific experts,” said Andrew Krouse, President and CEO of Cavion. “Julia is a proven executive in life sciences and shares our vision of developing first-in-class T-type calcium channel therapies aimed at improving function for people with movement disorders and rare neurological diseases.”
“I am excited to join Cavion at a pivotal time when the company is advancing toward late-stage clinical programs for essential tremor while expanding its pipeline,” said Ms. Gregory. “I look forward to working with the board and this talented team in trailblazing the development of neurological therapies where new solutions are desperately needed for patients.”
“We welcome Julia during this exciting time as we see incredible potential in the company’s proprietary science,” noted Steven Hall, PhD, Cavion Board member and General Partner of Lilly Ventures, a lead investor in the company. “Cavion’s pipeline of T-type calcium channel therapies extends beyond tremor to other neurological diseases that share a common pathophysiology and we look forward to initiating more clinical trials very soon.”
Julia Gregory joins Cavion with deep expertise and experience in the biopharmaceutical industry, having served as CEO of Five Prime Therapeutics and ContraFect Corporation and as Executive Vice President, Corporate Development and CFO of Lexicon Therapeutics. She is currently a member of the boards of directors of numerous biotech companies, including Biohaven Therapeutics Holding Company, Sosei Heptares Group and IMV, Inc. Ms. Gregory is also Chairman and CEO of the biotechnology financial and management advisory firm, Isometry Advisors, Inc. During her tenure in the industry, she has raised more than $1.5 billion across all stages of the business cycle and structured creative strategic alliances and transactions with pharmaceutical industry leaders, including GlaxoSmithKline, Bristol-Myers Squibb, Takeda, Genentech (now Roche), and Human Genome Sciences (now GSK).
About Cavion, Inc.
Cavion, Inc. is a privately held clinical stage biotechnology company creating therapies aimed at modulating the T-type calcium channel for the treatment of chronic and rare neurological diseases. Cavion’s portfolio of calcium channel modulators is being developed to restore the brain’s natural rhythms in a variety of neurological diseases such as essential tremor, Parkinson’s disease tremor, neuropathic pain, and epilepsy with absence seizures.
This press release contains forward-looking statements that are subject to risks and uncertainties and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Cavion, Inc. disclaims any intent or obligation to update forward-looking statements, except as required by law.
Lynn Blenkhorn, 508-851-0930
Source: Cavion, Inc.